Recombinant Human B7-2/CD86 protein (His Tag)
ED50
72-290 ng/mL
Species
Human
Purity
>95 %, SDS-PAGE
GeneID
942
Accession
P42081
验证数据展示
Technical Specifications
Purity | >95 %, SDS-PAGE |
Endotoxin Level | <1.0 EU/μg protein, LAL method |
Biological Activity |
Immobilized Human B7-2 (His tag) at 2 μg/mL (100 μL/well) can bind Human CD28 (hFc tag) with a linear range of 72-290 ng/mL. |
Source | HEK293-derived Human B7-2 protein Leu26-Pro247 (Accession# P42081) with His tag at the C-terminus. |
Predicted Molecular Mass | 26.2 kDa |
SDS-PAGE | 37-60 kDa, reducing (R) conditions |
Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
Storage |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
CD86 (also known as B7-2) is a costimulatory molecule belonging to the immunoglobulin (Ig) superfamily. CD86 is primarily expressed in antigen-presenting cells (APCs), including B cells, dendritic cells, and macrophages.CD86 has strong structural similarity with another B7 family molecule, CD80(B7-1).CD86 and CD80 are the ligands for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte antigen 4 (CTLA-4). The binding of CD86 or CD80 with CD28 antigen is a costimulatory signal for T cell activation, proliferation, and cytokine production. The binding of CD86 or CD80 with CTLA-4 negatively regulates T-cell activation and diminishes the immune response. However, CD86 and CD80 bind to CTLA-4 with higher affinity than CD28. Defects in CTLA-4-mediated transendocytosis of CD86 are associated with autoimmunity.
References:
1.Bolandi N, et al. (2021). Int J Mol Sci. 22(19):10719 2.Yokozeki H, et al. (1996). J Invest Dermatol.106(1):147-153 3.Baravalle G, et al. (2011). J Immunol. 187(6):2966-2973. 4.Collins M, et al. (2005). Genome Biol. 6(6):223 5.Greaves P, et al. (2013). Blood. 121(5):734-744 6.Kennedy A, et al. (2022). Nat Immunol.23(9):1365-1378